Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ZEBINIX (Maxx Pharma Pty Ltd)
Product name
ZEBINIX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
eslicarbazepine acetate
Registration type
NCE/NBE
Indication
ZEBINIX (tablet) is indicated as:
- monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;
- adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.